Publicaciones en colaboración con investigadores/as de University of Paris-Saclay (14)

2024

  1. A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

    Lung Cancer, Vol. 197

  2. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. Corrigendum: Practice-oriented solutions integrating intraoperative electron irradiation and personalized proton therapy for recurrent or unresectable cancers: Proof of concept and potential for dual FLASH effect, (Front. Oncol, (2022), 12, (1037262), 10.3389/fonc.2022.1037262)

    Frontiers in Oncology

2022

  1. Practice-oriented solutions integrating intraoperative electron irradiation and personalized proton therapy for recurrent or unresectable cancers: Proof of concept and potential for dual FLASH effect

    Frontiers in Oncology, Vol. 12

2021

  1. Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors

    Cancers, Vol. 13, Núm. 15

  2. Patterns of progression in patients treated for immuno-oncology antibodies combination

    Cancer Immunology, Immunotherapy, Vol. 70, Núm. 1, pp. 221-232

  3. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

    The Lancet Diabetes and Endocrinology, Vol. 9, Núm. 8, pp. 491-501

2020

  1. Identification of expression profiles defining distinct prognostic subsets of radioactive-iodine refractory differentiated thyroid cancer from the DECISION trial

    Molecular Cancer Therapeutics, Vol. 19, Núm. 1, pp. 312-317

2018

  1. Locally advanced cervical cancer with bladder invasion: Clinical outcomes and predictive factors for vesicovaginal fistulae

    Oncotarget, Vol. 9, Núm. 10, pp. 9299-9310

2017

  1. 3D waterfall plots: A better graphical representation of tumor response in oncology

    Annals of Oncology

  2. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 389, Núm. 10064, pp. 67-76

  3. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)

    European Journal of Cancer, Vol. 84, pp. 202-211

2016

  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920

2014

  1. The use of radiotherapy for early breast cancer in woman at different ages

    Clinical and Translational Oncology, Vol. 16, Núm. 8, pp. 680-685